Physician profile
Daniel Butler
NPI 1013320738
$347,146.71
in general payments reported to CMS, 2019-2025
19 companies · $240K in 2025
The $240K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.80 · 2022: $2,284 · 2023: $35K · 2024: $70K · 2025: $240K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $202K · Consulting Fee: $114K · Travel and Lodging: $18K · Food and Beverage: $6,822 · Honoraria: $4,440 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $202,257.50 |
| Consulting Fee | $113,696.19 |
| Travel and Lodging | $17,513.29 |
| Food and Beverage | $6,822.10 |
| Honoraria | $4,440.00 |
| Education | $118.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $92,244.46 | 2022-2025 | |
| Galderma Laboratories, L.P. | $85,871.46 | 2023-2025 | Nemluvio |
| Leo Pharma INC. | $70,113.36 | 2023-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $65,406.49 | 2023-2025 | Dupixent, Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14,208.06 | 2024-2025 | Spevigo |
| Novartis Pharmaceuticals Corporation | $7,532.18 | 2025 | |
| Abbvie INC. | $6,017.30 | 2020-2025 | Skyrizi |
| Sanofi US Services INC. | $2,870.00 | 2025 | |
| Arcutis Biotherapeutics, INC. | $2,052.13 | 2023-2025 | Zoryve |
| Pfizer INC. | $209.69 | 2024 | |
| Lilly USA, LLC | $150.62 | 2024 | |
| Regeneron Pharmaceuticals, INC. | $131.52 | 2022-2025 | Dupixent |
| Incyte Corporation | $125.92 | 2024-2025 | Opzelura |
| Janssen Biotech, INC. | $79.99 | 2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $38.94 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $33.20 | 2022 | |
| Amgen INC. | $30.92 | 2025 | Otezla |
| Dermavant Sciences, INC. | $30.47 | 2024 | Vtama |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.